Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.36 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.34 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.34 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20624810 | 1.00 | CA2 (0.44) | CA2PRKCDCA1ZDHHC7KMT2A | |
| SCHEMBL19404107 | 0.98 | CA2 (0.41) | CA2PRKCDCA1ZDHHC7KMT2A | |
| SCHEMBL18849861 | 0.98 | CA2 (0.41) | CA2PRKCDCA1ZDHHC7KMT2A | |
| SCHEMBL21664446 | 0.98 | CA2 (0.41) | CA2PRKCDCA1ZDHHC7KMT2A | |
| SCHEMBL18639268 | 0.98 | CA2 (0.41) | CA2PRKCDCA1ZDHHC7KMT2A | |
| SCHEMBL24974748 | 0.98 | CA2 (0.41) | CA2PRKCDCA1ZDHHC7KMT2A | |
| SCHEMBL20624783 | 0.98 | CA2 (0.41) | CA2PRKCDCA1ZDHHC7KMT2A | |
| SCHEMBL23256441 | 0.98 | CA2 (0.41) | CA2PRKCDCA1ZDHHC7KMT2A | |
| SCHEMBL19749275 | 0.98 | CA2 (0.41) | CA2PRKCDCA1ZDHHC7KMT2A | |
| SCHEMBL14286264 | 0.97 | PRKCD (0.39) | CA2PRKCDCA1ZDHHC7KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287030-A1 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | THE GENERAL HOSPITAL CORPORATION | 2023-09-14 | — | — | US | disclosed |
| US-11578320-B2 | High density sequencing and multiplexed priming | Singular Genomics Systems, Inc. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20220356466-A1 | HIGH DENSITY SEQUENCING AND MULTIPLEXED PRIMING | FIRST-CITIZENS BANK & TRUST COMPANY | 2022-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287030-A1 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | GALNT14, NEU4, CSGALNACT1 | CA2 2104/4885PRKCD 4725/4885CA1 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.